- Home
- OBIO vs FRD Comparison
OBIO vs FRD Comparison
Compare OBIO & FRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- FRD
- Stock Information
- Founded
- OBIO 2017
- FRD 1965
- Country
- OBIO United States
- FRD United States
- Employees
- OBIO N/A
- FRD N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- FRD Steel/Iron Ore
- Sector
- OBIO Health Care
- FRD Industrials
- Exchange
- OBIO Nasdaq
- FRD Nasdaq
- Market Cap
- OBIO 118.8M
- FRD 114.4M
- IPO Year
- OBIO N/A
- FRD N/A
- Fundamental
- Price
- OBIO $2.57
- FRD $16.89
- Analyst Decision
- OBIO Strong Buy
- FRD
- Analyst Count
- OBIO 4
- FRD 0
- Target Price
- OBIO $14.00
- FRD N/A
- AVG Volume (30 Days)
- OBIO 403.6K
- FRD 23.8K
- Earning Date
- OBIO 08-12-2025
- FRD 08-07-2025
- Dividend Yield
- OBIO N/A
- FRD 0.95%
- EPS Growth
- OBIO N/A
- FRD N/A
- EPS
- OBIO N/A
- FRD 1.21
- Revenue
- OBIO $2,944,000.00
- FRD $464,826,000.00
- Revenue This Year
- OBIO $20.47
- FRD N/A
- Revenue Next Year
- OBIO $11.45
- FRD N/A
- P/E Ratio
- OBIO N/A
- FRD $13.94
- Revenue Growth
- OBIO 41.61
- FRD N/A
- 52 Week Low
- OBIO $2.37
- FRD $12.24
- 52 Week High
- OBIO $7.04
- FRD $18.48
- Technical
- Relative Strength Index (RSI)
- OBIO 40.46
- FRD 58.15
- Support Level
- OBIO $2.50
- FRD $17.15
- Resistance Level
- OBIO $2.75
- FRD $17.71
- Average True Range (ATR)
- OBIO 0.18
- FRD 0.64
- MACD
- OBIO -0.03
- FRD 0.25
- Stochastic Oscillator
- OBIO 11.47
- FRD 72.78
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.